EGFR and non-small cell lung carcinoma: Again, a significant synergistic interaction between miR-34a mimics and erlotinib was revealed in NSCLC cells either with primary or acquired erlotinib resistance that indicated miR-34a-centered therapy could be used to increase EGFR-TKI sensitivity [57,58,59,60,169].